Title:
難治性小児固形腫瘍に対するハロゲン化キサンテンのインビトロ（ｉｎ ｖｉｔｏｒｏ）および異種移植片での抗腫瘍活性
Document Type and Number:
Japanese Patent JP7116252
Kind Code:
B2
Abstract:
A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.
Inventors:
Jamie Singer
Eric A. Wachter
lucy swift
Chunfeng Zian
Tanya Trippet
Al Narendran
Eric A. Wachter
lucy swift
Chunfeng Zian
Tanya Trippet
Al Narendran
Application Number:
JP2021514306A
Publication Date:
August 09, 2022
Filing Date:
May 15, 2019
Export Citation:
Assignee:
Provectus Pharmatech, Inc.
The Governor of the University of Calgary
The Governor of the University of Calgary
International Classes:
A61K31/352; A61K31/4745; A61K31/475; A61K31/704; A61K31/7048; A61K31/7068; A61K33/243; A61K41/00; A61P35/00; A61P43/00
Domestic Patent References:
| JP2014510728A |
Foreign References:
| WO2017009873A1 | ||||
| WO2017105993A1 |
Other References:
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS’ CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING,2018年04月25日
PRVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY,2018年04月28日
Journal of Pediatric Nursing,Vol.18, No.2,2003年,p.96-102
Journal of Clinical & Cellular Immunology,Vol.6, No.4,2015年
Provectus AnnouncesAgreement With POETIC(Pediatric OncologyExperimentalTherapeuticsInvestigatorsConsortium) To StudyPotential Of PV-10 ForPediatric Cancer,2016年12月08日
2018 ASCO ANNUAL MEETING ,10557,2018年06月02日,DOI:10.1200/JCO.2018.36.15_supppl.10557
PRVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY,2018年04月28日
Journal of Pediatric Nursing,Vol.18, No.2,2003年,p.96-102
Journal of Clinical & Cellular Immunology,Vol.6, No.4,2015年
Provectus AnnouncesAgreement With POETIC(Pediatric OncologyExperimentalTherapeuticsInvestigatorsConsortium) To StudyPotential Of PV-10 ForPediatric Cancer,2016年12月08日
2018 ASCO ANNUAL MEETING ,10557,2018年06月02日,DOI:10.1200/JCO.2018.36.15_supppl.10557
Attorney, Agent or Firm:
Hagiwara Makoto